AprilBio Co.,Ltd. (KOSDAQ:397030)
South Korea · Delayed Price · Currency is KRW 41,450
-1,650 (-3.83%)
At close: Jun 12, 2026
AprilBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 725.35 | 2,172 | 27,514 | - | 200 | 23,396 | |
Revenue Growth (YoY) | -97.56% | -92.11% | - | - | -99.15% | - |
Cost of Revenue | 23.46 | 22.95 | 16.38 | 19.05 | 26.27 | 19.21 |
Gross Profit | 701.89 | 2,149 | 27,498 | -19.05 | 173.73 | 23,377 |
Selling, General & Admin | 4,466 | 4,608 | 6,654 | 4,582 | 4,054 | 4,490 |
Research & Development | 4,789 | 4,022 | 3,205 | 8,038 | 6,925 | 13,892 |
Amortization of Goodwill & Intangibles | 0.76 | 0.74 | 0.68 | 0.68 | 0.67 | 0.61 |
Other Operating Expenses | 120.2 | 93.81 | 63.2 | 74.54 | 75.96 | 61.16 |
Operating Expenses | 10,048 | 9,413 | 10,629 | 13,369 | 11,648 | 18,930 |
Operating Income | -9,346 | -7,264 | 16,869 | -13,388 | -11,474 | 4,446 |
Interest Expense | -439.15 | -618.94 | -1,420 | -930.54 | -29.78 | -2,114 |
Interest & Investment Income | 3,117 | 3,331 | 3,312 | 3,149 | 1,309 | 262.92 |
Currency Exchange Gain (Loss) | 939.27 | -783.33 | 2,121 | 93.21 | 1,086 | -161.7 |
Other Non Operating Income (Expenses) | -3,732 | -3,734 | -754.03 | -3,028 | 149.97 | -55,147 |
EBT Excluding Unusual Items | -9,462 | -9,069 | 20,128 | -14,104 | -8,959 | -52,713 |
Gain (Loss) on Sale of Investments | -658.95 | -658.95 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | -0 | -25.87 | -0.01 | - |
Other Unusual Items | - | - | -122.8 | - | - | - |
Pretax Income | -10,121 | -9,728 | 20,005 | -14,130 | -8,959 | -52,713 |
Net Income | -10,121 | -9,728 | 20,005 | -14,130 | -8,959 | -52,713 |
Net Income to Common | -10,121 | -9,728 | 20,005 | -14,130 | -8,959 | -52,713 |
Shares Outstanding (Basic) | 23 | 23 | 22 | 21 | 20 | 8 |
Shares Outstanding (Diluted) | 23 | 23 | 22 | 21 | 20 | 8 |
Shares Change (YoY) | 1.41% | 3.41% | 2.66% | 9.11% | 134.61% | 139.04% |
EPS (Basic) | -449.15 | -429.34 | 913.00 | -662.00 | -458.00 | -6322.00 |
EPS (Diluted) | -449.15 | -429.34 | 913.00 | -662.00 | -458.00 | -6322.00 |
Free Cash Flow | -4,294 | -3,630 | 21,514 | -10,571 | -6,794 | 2,546 |
Free Cash Flow Per Share | -190.57 | -160.22 | 981.88 | -495.25 | -347.29 | 305.34 |
Gross Margin | 96.77% | 98.94% | 99.94% | - | 86.87% | 99.92% |
Operating Margin | -1288.55% | -334.44% | 61.31% | - | -5737.15% | 19.00% |
Profit Margin | -1395.28% | -447.88% | 72.71% | - | -4479.64% | -225.31% |
Free Cash Flow Margin | -591.99% | -167.14% | 78.19% | - | -3396.76% | 10.88% |
EBITDA | -8,674 | -6,574 | 17,575 | -12,714 | -10,881 | 4,934 |
EBITDA Margin | - | - | 63.88% | - | - | 21.09% |
D&A For EBITDA | 672.5 | 689.55 | 706.33 | 674.42 | 593.44 | 487.25 |
EBIT | -9,346 | -7,264 | 16,869 | -13,388 | -11,474 | 4,446 |
EBIT Margin | - | - | 61.31% | - | - | 19.00% |
Advertising Expenses | - | 1.53 | - | - | 14.33 | 3.5 |